[A23-65] Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V

Last updated 02.10.2023

Project no.:

Commission awarded on 03.07.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after 2 or more lines of systemic therapy

Result of dossier assessment:
  • If high-dose therapy is an option: added benefit not proven
  • If high-dose therapy is not an option: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form